SML2126
NS1209
≥98% (HPLC)
别名:
(RS)-NS 1209, 2-[[[5-[4-[(Dimethylamino)sulfonyl]phenyl]-1,2,6,7,8,9-hexahydro-8-methyl-2-oxo-3H-pyrrolo[3,2-h]isoquinolin-3-ylidene]amino]oxy]-4-hydroxybutanoic acid, NS 1209, SPD 502, SPD502
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
Assay:
≥98% (HPLC)
Form:
powder
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
SMILES string
CN1CCC(C(C2=CC=C(S(=O)(N(C)C)=O)C=C2)=CC(C3=NOC(CCO)C(O)=O)=C4NC3=O)=C4C1
InChI
1S/C24H28N4O7S/c1-27(2)36(33,34)15-6-4-14(5-7-15)17-12-18-21(19-13-28(3)10-8-16(17)19)25-23(30)22(18)26-35-20(9-11-29)24(31)32/h4-7,12,20,29H,8-11,13H2,1-3H3,(H,31,32)(H,25,26,30)
InChI key
CFJRSKULEDUDKL-UHFFFAOYSA-N
Biochem/physiol Actions
NS1209 (SPD 502) is a potent, selective, water-soluble and in vivo long-lasting AMPA antagonist. NS1209 exhibits neuroprotective activity in animal models of stroke, neuropathic pain and epilepsy.
water-soluble and in vivo long-lasting AMPA antagonist with neuroprotective activity
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Anne Sabers et al.
Epilepsy research, 106(1-2), 292-295 (2013-04-30)
Refractory status epilepticus (RSE) is a life-threatening condition that requires immediate and aggressive treatment. Unfortunately, sometimes standard antiepileptic treatment is insufficient. Furthermore, alternative therapeutic options are limited by low evidence of efficacy. The primary objective of this study was to
E O Nielsen et al.
The Journal of pharmacology and experimental therapeutics, 289(3), 1492-1501 (1999-05-21)
Accumulating preclinical data suggest that compounds that block the excitatory effect of glutamate on excitatory amino acid receptors may have neuroprotective effects and utility for the treatment of neurodegeneration after brain ischemia. In the present study, the in vitro and
Jan M Keppel Hesselink
Drug development research, 78(2), 75-80 (2017-02-15)
Preclinical Research The selective AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonist, NS1209 (also known as SPD 502) has been explored in several research and development campaigns since its selection as a lead drug candidate in the early 1990s by the Danish biotechnology